Capromorelin

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameCapromorelin
Drug Alias Name卡莫瑞林CapromorelinumCapromorelinaCP-424391-18RQ-00000005 +[8] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGhrelin/growth hormone secretagogue receptor agonists
TargetsGhrelin/growth hormone secretagogue receptor
Therapy Area/IndicationsHealthy AgingJoint Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRaqualia Pharma IncPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRaqualia Pharma IncPfizer Inc
Active IndicationsN/A
Inactive IndicationsHealthy AgingJoint Diseases

Other Information

ATC CodeN/A
Related LinksWikipedia